HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives

被引：15

作者：

Belema, Makonen ^{[1
]}

Nguyen, Van N. ^{[1
]}

St. Laurent, Denis R. ^{[1
]}

Lopez, Omar D. ^{[1
]}

Qiu, Yuping ^{[1
]}

Good, Andrew C. ^{[3
]}

Nower, Peter T. ^{[2
]}

Valera, Lourdes ^{[2
]}

O'Boyle, Donald R., II ^{[2
]}

Sun, Jin-Hua ^{[2
]}

Liu, Mengping ^{[2
]}

Fridell, Robert A. ^{[2
]}

Lemm, Julie A. ^{[2
]}

Gao, Min ^{[2
]}

Knipe, Jay O. ^{[4
]}

Meanwell, Nicholas A. ^{[1
]}

Snyder, Lawrence B. ^{[1
]}

机构：

[1] Bristol Myers Squibb Res & Dev, Dept Med Chem, Wallingford, CT 06492 USA

[2] Bristol Myers Squibb Res & Dev, Dept Virol, Wallingford, CT 06492 USA

[3] Bristol Myers Squibb Res & Dev, Dept Comp Aided Drug Design, Wallingford, CT 06492 USA

[4] Bristol Myers Squibb Res & Dev, Dept Metab & Pharmacokinet, Wallingford, CT 06492 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 15期

关键词：

Daclatasvir; HCV; NS5A; Mandelamide X-ray; Pan-genotype HCV replicon inhibition; Phenylglycine; HEPATITIS-C VIRUS; PLUS RIBAVIRIN; THERAPY; DACLATASVIR; ASUNAPREVIR; INFECTION;

D O I：

10.1016/j.bmcl.2013.05.040

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The isoquinolinamide series of HCV NS5A inhibitors exemplified by compounds 2b and 2c provided the first dual genotype-1a/1b (GT-1a/1b) inhibitor class that demonstrated a significant improvement in potency toward GT-1a replicons compared to that of the initial program lead, stilbene 2a. Structure-activity relationship (SAR) studies that uncovered an alternate phenylglycine-based cap series that exhibit further improvements in virology profile, along with some insights into the pharmacophoric elements associated with the GT-1a potency, are described. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：4428 / 4435

页数：8

共 50 条

[1] Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor
Zhong, Min
Peng, Eric
Huang, Ningwu
Huang, Qi
Huq, Anja
Lau, Meiyen
Colonno, Richard
Li, Leping
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (18) : 4508 - 4512
[2] HCV NS5A replication complex inhibitors. Part 31: discovery of potent analogs with distinct core topologies
Lopez, Omar D.
Nguyen, Van N.
St Laurent, Denis R.
Belema, Makonen
Serrano-Wu, Michael H.
Goodrich, Jason T.
Yang, Fukang
Qiu, Yuping
Ripka, Amy S.
Nower, Peter T.
Valera, Lourdes
Liu, Mengping
O'Boyle, Donald R., II
Sun, Jin-Hua
Fridell, Robert A.
Lemm, Julie A.
Gao, Min
Good, Andrew C.
Meanwell, Nicholas A.
Snyder, Lawrence B.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (03) : 779 - 784
[3] Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core
Yu, Wensheng
Hu, Bin
Zhong, Bin
Hao, Jinglai
Lei, Zhixin
Agrawal, Sony
Rokosz, Laura
Liu, Rong
Chen, Shiying
Asante-Appiah, Ernest
Kozlowski, Joseph A.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (05) : 700 - 706
[4] Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A
DeGoey, David A.
Randolph, John T.
Liu, Dachun
Pratt, John
Hutchins, Charles
Donner, Pamela
Krueger, A. Chris
Matulenko, Mark
Patel, Sachin
Motter, Christopher E.
Nelson, Lissa
Keddy, Ryan
Tufano, Michael
Caspi, Daniel D.
Krishnan, Preethi
Mistry, Neeta
Koev, Gennadiy
Reisch, Thomas J.
Mondal, Rubina
Pilot-Matias, Tami
Gao, Yi
Beno, David W. A.
Maring, Clarence J.
Molla, Akhter
Dumas, Emily
Campbell, Andrew
Williams, Laura
Collins, Christine
Wagner, Rolf
Kati, Warren M.
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (05) : 2047 - 2057
[5] Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect
Belema, Makonen
Meanwell, Nicholas A.
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (12) : 5057 - 5071
[6] IDENIX NS5A HCV REPLICATION INHIBITORS WITH LOW PICOMOLAR, PAN-GENOTYPIC IN VITRO ANTIVIRAL ACTIVITY
Dousson, C. B.
Chapron, C.
Standring, D.
Bilello, J. P.
McCarville, J.
La Colla, M.
Seifer, M.
Parsy, C.
Dukhan, D.
Pierra, C.
Surleraux, D.
JOURNAL OF HEPATOLOGY, 2011, 54 : S326 - S327
[7] Samatasvir (IDX719), a potent pan-genotypic HCV NS5A inhibitor
Mayers, D.
JOURNAL OF VIRAL HEPATITIS, 2013, 20 : 25 - 26
[8] HCV NS5A inhibitors excellent with pan-genotypic picomolar potency and better stability
Zhan, Zheng-Yun
Yan, Hua
Li, Qing
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
[9] Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate
Ramdas, Vidya
Talwar, Rashmi
Banerjee, Moloy
Joshi, Advait Arun
Das, Amit Kumar
Walke, Deepak Sahebrao
Borhade, Prashant
Dhayagude, Usha
Loriya, Rajesh
Gote, Ganesh
Bommakanti, Apparao
Sivaram, Aruna
Agarwal, Gautam
Goswami, Arnab
Nigade, Prashant
Mehta, Maneesh
Patil, Vinod
Modi, Dipak
Kumar, Hemant
Mallurwar, Sadanand
Dash, Amruta
Modi, Falguni
Kuldharan, Sandip
Srivastava, Pratima
Singh, Minakshi
Narasimham, Lakshmi
Gundu, Jayasagar
Sharma, Sharad
Kamboj, Rajender Kumar
Palle, Venkata P.
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (23) : 10563 - 10582
[10] HCV NS5A replication complex inhibitors. Part 2: Investigation of stilbene prolinamides
St Laurent, Denis R.
Belema, Makonen
Gao, Min
Goodrich, Jason
Kakarla, Ramesh
Knipe, Jay O.
Lemm, Julie A.
Liu, Mengping
Lopez, Omar D.
Nguyen, Van N.
Nower, Peter T.
O'Boyle, Donald, II
Qiu, Yuping
Romine, Jeffrey L.
Serrano-Wu, Michael H.
Sun, Jin-Hua
Valera, Lourdes
Yang, Fukang
Yang, Xuejie
Meanwell, Nicholas A.
Snyder, Lawrence B.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (19) : 6063 - 6066

← 1 2 3 4 5 →